RxDoctor Payments DataLook up a doctor →

Jeffrey Carr, MD

Interventional Cardiology · Tyler, TXNPI 1649260373

Payments from drug & device makers

$2,711,534in general payments, 2019–2025

Across 1,098 payments — averaging $2469.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Bard Peripheral Vascular, Inc.$1.8M
  • Novo Nordisk AS$541K
  • Medtronic$121K
  • Philips North America LLC$92K
  • Novartis$70K
  • Venclose Inc.$38K
  • plus $95K from 49 others

What the payments were for

  • Royalty or licence$57,1343%
  • Consulting fees$203,51511%
  • Speaking & faculty fees$90,6995%
  • Travel & lodging$19,6891%
  • Food & beverage$17,6631%
  • Education$20%
  • Other$1,497,69179%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,711,534 in reported general payments places this provider in the 95th percentile of 686 interventional cardiology providers in Texas.

See all interventional cardiology providers in Texas

Medicare billing

Part B allowed, 2024
$221,557
Medicare patients
1,419
Services billed
3,411

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XareltoRivaroxaban120$126,020
EliquisApixaban101$80,206
EntrestoSacubitril/Valsartan57$61,500
BrilintaTicagrelor39$32,013
Praluent PenAlirocumab17$10,923
Repatha SureclickEvolocumab11$9,199
JardianceEmpagliflozin14$8,891
Metoprolol Succinate318$6,300
Rosuvastatin Calcium173$3,173
Nebivolol Hcl46$3,059
Cilostazol138$2,780
ClopidogrelClopidogrel Bisulfate239$2,678
Torsemide106$2,501
Ranolazine ErRanolazine28$2,369
Isosorbide Mononitrate ErIsosorbide Mononitrate202$1,963

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonXarelto$723$126,020120 claims
PfizerEliquis$13$80,206101 claims
NovartisEntresto$70,412$61,50057 claims
AstraZenecaBrilinta$54$32,01339 claims
Boehringer IngelheimJardiance$70$8,89114 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 686 interventional cardiology providers in Texas.

Other interventional cardiology in Tyler

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →